ArticleScientific reports2026
High magnitude of carbapenemase-producing Acinetobacter baumannii in sepsis patients at Ethiopian referral hospitals: a whole genome analysis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenemase-producing Acinetobacter baumannii (CP-Ab) is a critical priority pathogen. Between October 2019 and September 2020, a multicentre study was conducted at four Ethiopian hospitals: Tikur Anbessa and Yekatit (central), Hawassa (southern), and Dessie (northern). A total of 1416 sepsis patients were enrolled, and blood cultures were performed. Acinetobacter isolates were confirmed using MALDI-TOF and tested for carbapenem susceptibility. All Acinetobacter isolates were subjected to whole-genome sequencing. Selected isolates underwent nanopore sequencing through Plasmidsaurus. Forty-five Acinetobacter isolates were identified, mostly A. baumannii (n = 38), with a few other species (n = 7). Among the 38 A. baumannii isolates, 18 carried blaNDM−1 and either blaOXA−23 or blaOXA−58 carbapenemase genes concurrently. blaOXA−58 and blaNDM−1 were co-located on plasmids of sizes 80 kb to 113 kb. blaOXA−66 (n = 13) and blaOXA−69 (n = 12) were frequently identified chromosomally encoded carbapenemase genes. Several STs of A. baumannii were identified, with ST2 (n = 14) and ST1 (n = 13) being frequent. One A. nosocomialis carried blaNDM−1 and blaOXA−58 simultaneously. Several other genes were identified that confer resistance to aminoglycosides (n = 37), phenicol (n = 19), trimethoprim (n = 16), macrolides (n = 25), quinolones (n = 10), tetracyclines (n = 22), sulphonamides (n = 36), and disinfectants (n = 23). The high prevalence of carbapenemase-producing A. baumannii and other Acinetobacter species underscores the need for nationwide antibiotic stewardship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.